Pre-made Modotuximab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Modotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Modotuximab (INN; formerly zatuximab) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER1.
| Products Name (INN Index) | Pre-Made Modotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody |
|---|---|
| INN Name | Modotuximab |
| Target | EGFR |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2014 |
| Companies | Symphogen,Merck |
| Conditions Approved | NA |
| Conditions Active | Colorectal cancer,Glioma,Non-small cell lung cancer |
| Conditions Discontinued | Head and neck cancer,Oesophageal cancer |
| Development Tech | NA |
| Previous Name | Zatuximab |
| Gm Offical Target Name | EGFR |
| Package |
